search
Back to results

CKD-828 (80/5mg) Pharmacokinetic Study

Primary Purpose

Hypertension

Status
Completed
Phase
Phase 1
Locations
Korea, Republic of
Study Type
Interventional
Intervention
CKD-828
Telmisartan
S-amlodipine
Sponsored by
Chong Kun Dang Pharmaceutical
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Hypertension focused on measuring Hypertension, CKD-828, Telmisartan, S-amlodipine, Pharmacokinetic

Eligibility Criteria

19 Years - 55 Years (Adult)MaleAccepts Healthy Volunteers

Inclusion Criteria:

  • A healthy volunteer between 20 and 55 years old
  • More than 50kg and within 20% of ideal body weight
  • No any congenital or chronic diseases and medical symptom
  • Appropriate for the study from examination(laboratory test, ECG etc.) within 4weeks prior to the first IP administration
  • Signed the informed consent form prior to the study participation.

Exclusion Criteria:

  • History of relevant hypersensitivity against drug
  • Clinical significant disease or medical history (ex. hepato/cholangio, cardio, endo, hemato, onco, CNS etc.)
  • Active liver disease or abnormal laboratory result (AST or ALT or Total bilirubin > 1.5*ULN)
  • SBP <90mmHg or SBP >150mmHg
  • DBP <50mmHg or DBP >100mmHg
  • Creatinine clearance <80mL/min
  • A Disease(ex.inflammatory intestinal disease, gastric or duodenal ulcer ,hepatic disease history , gastro-intestinal surgery except for appendectomy)that may influence on the absorption, distribution, metabolism and excretion of the drug
  • The evidence of severe attack or acute disease or surgical intervention within 28 days prior to the first IP administration.
  • A drug abuse or a heavy caffeine consumer (more than 5 cups per a day) or regular alcohol consumer(more than 21 units/week) or a heavy smoker(more than 10 cigarettes per a day)
  • Taking ETC medicine or oriental medicine within 14days or Taking OTC medicine within 7days prior to the first IP administration
  • Abnormal diet(Especially, grapefruit juice within 7 days prior to the first IP administration) that may influence on the absorption, distribution, metabolism and excretion of the drug

Sites / Locations

  • Kyungpook National University Hospital

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Active Comparator

Arm Label

CKD-828(Fixed Dose Combination)

Combination Therapy

Arm Description

FDC tablet consisting of Telmisartan 80mg/S-Amlodipine 5mg

Coadministration of Telmisartan 80mg and S-amlodipine 5mg

Outcomes

Primary Outcome Measures

Cmax after administration of CKD-828(Fixed Dose Combination) tablet and coadministration of corresponding dose of telmisartan and s-amlodipine.
AUClast after administration of CKD-828(Fixed Dose Combination) tablet and coadministration of corresponding dose of telmisartan and s-amlodipine.

Secondary Outcome Measures

Tmax after administration of CKD-828(Fixed Dose Combination) tablet and coadministration of corresponding dose of telmisartan and s-amlodipine.
t1/2 after administration of CKD-828(Fixed Dose Combination) tablet and coadministration of corresponding dose of telmisartan and s-amlodipine.
AUCinf after administration of CKD-828(Fixed Dose Combination) tablet and coadministration of corresponding dose of telmisartan and s-amlodipine.
Number of participants with adverse events
Adverse Event monitoring Evaluated safety parameters included: Physical examination, Vital sign, ECG, laboratory test

Full Information

First Posted
September 22, 2014
Last Updated
April 8, 2015
Sponsor
Chong Kun Dang Pharmaceutical
search

1. Study Identification

Unique Protocol Identification Number
NCT02250833
Brief Title
CKD-828 (80/5mg) Pharmacokinetic Study
Official Title
To Compare the Pharmacokinetics and Safety of CKD-828 80/5mg to Coadministration of Telmisartan 80mg and S-amlodipine 5mg in Healthy Male Volunteers
Study Type
Interventional

2. Study Status

Record Verification Date
April 2015
Overall Recruitment Status
Completed
Study Start Date
September 2014 (undefined)
Primary Completion Date
December 2014 (Actual)
Study Completion Date
December 2014 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Chong Kun Dang Pharmaceutical

4. Oversight

Data Monitoring Committee
No

5. Study Description

Brief Summary
A randomized, open-label, single-dose, two-period, two-way, crossover study to compare the pharmacokinetics and safety CKD-828 (Fixed Dose Combination Tablet) to coadministration telmisartan and s-amlodipine in health volunteers.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Hypertension
Keywords
Hypertension, CKD-828, Telmisartan, S-amlodipine, Pharmacokinetic

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 1
Interventional Study Model
Crossover Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
69 (Actual)

8. Arms, Groups, and Interventions

Arm Title
CKD-828(Fixed Dose Combination)
Arm Type
Experimental
Arm Description
FDC tablet consisting of Telmisartan 80mg/S-Amlodipine 5mg
Arm Title
Combination Therapy
Arm Type
Active Comparator
Arm Description
Coadministration of Telmisartan 80mg and S-amlodipine 5mg
Intervention Type
Drug
Intervention Name(s)
CKD-828
Other Intervention Name(s)
Telminuvo
Intervention Description
Telmisartan 80mg /S-Amlodipine 5mg(FDC) Tablet, Oral, Once Daily
Intervention Type
Drug
Intervention Name(s)
Telmisartan
Other Intervention Name(s)
Micardis
Intervention Description
- Telmisartan 80mg tablet, Oral, Once Daily (Combination Therapy with S-amlodipine)
Intervention Type
Drug
Intervention Name(s)
S-amlodipine
Other Intervention Name(s)
Anydipine s
Intervention Description
- S-amlodipine 5mg tablet, Oral, Once Daily (combination Therapy with Telmisartan)
Primary Outcome Measure Information:
Title
Cmax after administration of CKD-828(Fixed Dose Combination) tablet and coadministration of corresponding dose of telmisartan and s-amlodipine.
Time Frame
up to 168 hours post dose
Title
AUClast after administration of CKD-828(Fixed Dose Combination) tablet and coadministration of corresponding dose of telmisartan and s-amlodipine.
Time Frame
up to 168 hours post dose
Secondary Outcome Measure Information:
Title
Tmax after administration of CKD-828(Fixed Dose Combination) tablet and coadministration of corresponding dose of telmisartan and s-amlodipine.
Time Frame
up to 168 hours post dose
Title
t1/2 after administration of CKD-828(Fixed Dose Combination) tablet and coadministration of corresponding dose of telmisartan and s-amlodipine.
Time Frame
up to 168 hours post dose
Title
AUCinf after administration of CKD-828(Fixed Dose Combination) tablet and coadministration of corresponding dose of telmisartan and s-amlodipine.
Time Frame
up to 168 hours post dose
Title
Number of participants with adverse events
Description
Adverse Event monitoring Evaluated safety parameters included: Physical examination, Vital sign, ECG, laboratory test
Time Frame
up to 31days post dose

10. Eligibility

Sex
Male
Minimum Age & Unit of Time
19 Years
Maximum Age & Unit of Time
55 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria: A healthy volunteer between 20 and 55 years old More than 50kg and within 20% of ideal body weight No any congenital or chronic diseases and medical symptom Appropriate for the study from examination(laboratory test, ECG etc.) within 4weeks prior to the first IP administration Signed the informed consent form prior to the study participation. Exclusion Criteria: History of relevant hypersensitivity against drug Clinical significant disease or medical history (ex. hepato/cholangio, cardio, endo, hemato, onco, CNS etc.) Active liver disease or abnormal laboratory result (AST or ALT or Total bilirubin > 1.5*ULN) SBP <90mmHg or SBP >150mmHg DBP <50mmHg or DBP >100mmHg Creatinine clearance <80mL/min A Disease(ex.inflammatory intestinal disease, gastric or duodenal ulcer ,hepatic disease history , gastro-intestinal surgery except for appendectomy)that may influence on the absorption, distribution, metabolism and excretion of the drug The evidence of severe attack or acute disease or surgical intervention within 28 days prior to the first IP administration. A drug abuse or a heavy caffeine consumer (more than 5 cups per a day) or regular alcohol consumer(more than 21 units/week) or a heavy smoker(more than 10 cigarettes per a day) Taking ETC medicine or oriental medicine within 14days or Taking OTC medicine within 7days prior to the first IP administration Abnormal diet(Especially, grapefruit juice within 7 days prior to the first IP administration) that may influence on the absorption, distribution, metabolism and excretion of the drug
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Young-Ran Yoon
Organizational Affiliation
Kyungpook National University Hospital Clinical Trial Center
Official's Role
Principal Investigator
Facility Information:
Facility Name
Kyungpook National University Hospital
City
Daegu, samdeok-dong, 2-ga 50
State/Province
samdeok-dong, 2-ga 50 Jung-gu
ZIP/Postal Code
700-721
Country
Korea, Republic of

12. IPD Sharing Statement

Learn more about this trial

CKD-828 (80/5mg) Pharmacokinetic Study

We'll reach out to this number within 24 hrs